Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis

Inclusion Criteria:

• Voluntary provision of written informed consent and ability to comply with protocolrequirements.

• Age ≥18 years, any gender.

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.

• Confirmed diagnosis of primary light-chain (AL) amyloidosis.

• Relapsed or refractory primary AL amyloidosis.

• Measurable hematologic disease at screening (per protocol-defined criteria).

• Involvement of ≥1 amyloid-affected organ.

• Adequate organ function meeting all protocol-specified criteria within 3 days priorto first dose.

Exclusion Criteria:

• Current or prior diagnosis of multiple myeloma.

• Received anti-AL amyloidosis therapy within protocol-specified timeframe prior tofirst dose.

• Clinically significant cardiovascular or cerebrovascular disease.

• Any active or uncontrolled infection meeting protocol-defined criteria.

• Any other condition deemed by the Investigator to preclude safe study participation.